CPA
GLSI icon

Capital Performance Advisors’s Greenwich LifeSciences GLSI Stock Holding History

Capital Performance Advisors’s Portfolio GLSI Stock Details GLSI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1
Closed -$14 – 1152
2024
Q3 		$14 Buy
+1
New +$15 ﹤0.01% 2869

Other funds holding GLSI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $38.1B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SO
STRS Ohio Columbus, Ohio $25.2B AUM 30.31% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Capital Performance Advisors's GLSI Position: Q4 2024 in Review

Capital Performance Advisors sold out of Greenwich LifeSciences (GLSI) in Q4 2024, closing a stake of 1 share — an estimated $14 sold.

Capital Performance Advisors first reported a position in GLSI in Q3 2024 and held it in 1 quarter. The position peaked at $14 in Q3 2024. 42 funds tracked by Wall St. Rank hold GLSI as of Q4 2024.

  • Capital Performance Advisors reported no remaining Greenwich LifeSciences position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 1 Greenwich LifeSciences share in Q4 2024, an estimated $14.
  • Capital Performance Advisors first reported a position in Greenwich LifeSciences in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Greenwich LifeSciences position peaked at $14 in Q3 2024.
  • 42 funds tracked by Wall St. Rank held Greenwich LifeSciences as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.